```html

Y‑90 Hepatic Radioembolization‑Induced Pneumonitis

Overview

Y‑90 hepatic radioembolization (also called selective internal radiation therapy, SIRT) is a minimally invasive procedure used to treat primary or metastatic liver cancer. Tiny glass or resin beads loaded with the beta‑emitting radioisotope yttrium‑90 (Y‑90) are delivered through the hepatic artery directly into the tumor’s blood supply. While the therapy is highly targeted, a small fraction of the radioactive particles can travel to the lungs through microscopic arteriovenous shunts, depositing radiation in pulmonary tissue. This inadvertent lung exposure can trigger an inflammatory reaction known as **Y‑90 hepatic radioembolization‑induced pneumonitis**.

Who it affects: The condition is most commonly seen in patients undergoing Y‑90 treatment for hepatocellular carcinoma (HCC) or colorectal liver metastases. Because the procedure is typically offered to adults with advanced liver disease, the majority of affected individuals are 55–75 years old, but it can occur at any age.

Prevalence: Reported rates of clinically significant pneumonitis range from 0.5 % to 5 % in large series, depending on the type of microsphere (glass vs. resin) and the degree of lung shunt fraction measured before treatment.<sup>1</sup> In routine practice, most patients experience only low‑grade radiation pneumonitis that resolves with observation or steroids.

Symptoms

Radiation‑induced pneumonitis typically develops 2 weeks to 6 months after the Y‑90 procedure. The severity varies; mild cases may be asymptomatic, while moderate to severe cases present with the following manifestations:

• Dry cough – Persistent, non‑productive cough that does not improve with typical cough medicines.
• Dyspnea (shortness of breath) – Ranges from mild on exertion to severe at rest.
• Chest discomfort – Can feel like a tightness, pressure, or mild pain, often worsening with deep breaths.
• Fever – Low‑grade (≤38 °C/100.4 °F) is common; high fevers may suggest secondary infection.
• Fatigue – Generalized weakness that interferes with daily activities.
• Wheezing or crackles – Heard on auscultation; “fine crackles” (rales) are typical.
• Weight loss – Unintentional loss due to decreased appetite and increased metabolic demand.
• Hypoxia – Low oxygen saturation (<92 %) on room air, especially during exertion.
• Interstitial infiltrates on imaging – Ground‑glass opacities or reticular patterns seen on CT; not a symptom but often prompts evaluation.

Symptoms usually evolve gradually, but a sudden worsening may signal an infection or progression to radiation‑associated fibrosis, which requires urgent medical attention.

Causes and Risk Factors

Primary cause

The underlying mechanism is radiation‑induced inflammation of the alveolar walls. When Y‑90 microspheres enter the pulmonary circulation, the beta particles deposit energy over a short distance (mean tissue penetration ≈2.5 mm). The resulting cellular injury triggers cytokine release (e.g., TNF‑α, IL‑6), fibroblast activation and edema, ultimately producing the clinical picture of pneumonitis.

Key risk factors

• High lung shunt fraction (LSF) – Measured by technetium‑99m macro‑aggregated albumin (MAA) scan before therapy. An LSF > 20 % (glass beads) or > 15 % (resin beads) markedly increases risk.
• Large total administered activity – Doses > 2 GBq (glass) or > 3 GBq (resin) raise cumulative lung dose.
• Pre‑existing lung disease – COPD, interstitial lung disease, or prior radiation to the chest.
• Smoking history – Current or former smokers have reduced pulmonary reserve.
• Age > 70 years – Age‑related decline in immune regulation can amplify inflammatory responses.
• Concurrent systemic therapy – Chemotherapy or immunotherapy given close to Y‑90 may potentiate lung toxicity.

Diagnosis

Because symptoms overlap with infection, heart failure, or disease progression, a systematic approach is vital.

1. Clinical assessment

• Detailed history of Y‑90 treatment dates, administered activity, and pre‑procedure LSF.
• Symptom timeline and any recent infections or medication changes.

2. Physical examination

• Observe for tachypnea, use of accessory muscles, and auscultatory crackles.
• Check oxygen saturation (pulse oximetry) at rest and after a 6‑minute walk test.

3. Imaging studies

• Chest X‑ray – May show diffuse hazy opacities; useful as a quick screen.
• High‑resolution computed tomography (HRCT) – Gold standard; reveals ground‑glass opacities, often bilateral and peripheral, sometimes with a “crazy‑paving” pattern.
• Ventilation‑Perfusion (V/Q) scan – Helpful to differentiate radiation pneumonitis from pulmonary embolism.

4. Laboratory tests

• Complete blood count (CBC) – Look for leukocytosis that might suggest infection.
• C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – Elevated in inflammation but nonspecific.
• Arterial blood gas (ABG) – Determines oxygenation and carbon dioxide retention.

5. Exclusion of other causes

Bronchoscopy with bronchoalveolar lavage (BAL) may be performed if infection, hemorrhage, or malignancy cannot be ruled out.

Diagnostic criteria (adapted from the American Thoracic Society)

1. History of Y‑90 radioembolization with documented lung shunt.
2. New or worsening respiratory symptoms 2 weeks–6 months post‑procedure.
3. Radiologic findings consistent with radiation pneumonitis.
4. No alternative diagnosis (e.g., infection, heart failure) that better explains the picture.

Treatment Options

Management focuses on controlling inflammation, preserving lung function, and preventing secondary infection.

Pharmacologic therapy

• Corticosteroids – First‑line. Prednisone 0.5–1 mg/kg daily for 2–4 weeks, then a gradual taper over 6–8 weeks. Intravenous methylprednisolone may be used for severe cases.
• Inhaled steroids – Budesonide or fluticasone can be added for mild disease or during steroid taper.
• Bronchodilators – Short‑acting beta‑agonists (e.g., albuterol) for wheezing; long‑acting agents for chronic dyspnea.
• Antibiotics – Empiric coverage only if bacterial infection is suspected; cultures guide selection.
• Antifibrotic agents – Nintedanib or pirfenidone are under investigation for radiation‑induced fibrosis; not routine yet.

Supportive measures

• Supplemental oxygen to keep SpO₂ ≥ 94 % (or ≥ 88 % in COPD patients).
• Pulmonary rehabilitation – Breathing exercises, interval walking, and strength training.
• Vaccinations – Annual influenza and pneumococcal vaccines to reduce infection risk.
• Hydration and nutrition – Adequate fluid intake and protein‑rich diet to aid tissue repair.

Procedural interventions (rare)

• Bronchoscopy with BAL – Diagnostic, occasionally therapeutic if secretions are thick.
• Mechanical ventilation – Reserved for respiratory failure unresponsive to non‑invasive support.

When to modify cancer therapy

If pneumonitis is moderate‑to‑severe (grade ≥ 3), the treating oncology team may delay or adjust subsequent Y‑90 treatments, systemic chemotherapy, or immunotherapy until pulmonary status stabilizes.

Living with Y‑90 Hepatic Radioembolization‑Induced Pneumonitis

While the condition can be unsettling, many patients recover fully with appropriate care. Below are practical tips for daily life.

Monitoring and follow‑up

• Schedule a pulmonary follow‑up 4–6 weeks after starting steroids, then every 3 months for the first year.
• Keep a symptom diary – note cough frequency, breathlessness with activity, and any fever.
• Use a home pulse oximeter; seek care if resting SpO₂ falls below 92 %.

Activity and exercise

• Begin with low‑impact activities: walking, stationary cycling, or gentle yoga.
• Aim for 150 minutes of moderate activity per week, as tolerated.
• Avoid high‑altitude environments (> 2,500 m) until lung function stabilizes.

Breathing techniques

• Pursed‑lip breathing – Helps keep airways open during exhalation.
• Diaphragmatic breathing – Reduces work of breathing and improves oxygenation.

Environmental considerations

• Stay indoors on high‑pollution or wildfire days; use HEPA filters when possible.
• Avoid exposure to secondhand smoke and occupational dusts.
• Maintain indoor humidity between 30–50 % to keep airways moist.

Medication adherence

• Take steroids exactly as prescribed; never stop abruptly to avoid adrenal insufficiency.
• Set reminders for tapering schedules and pharmacy refills.
• Report side effects (e.g., mood changes, hyperglycemia) to your provider promptly.

Emotional support

• Join support groups for liver cancer or radiation therapy patients.
• Consider counseling or mindfulness programs to manage anxiety related to breathlessness.

Prevention

Because the condition stems from unintended lung radiation, most preventive strategies are applied before the Y‑90 procedure.

1. Pre‑procedure lung shunt assessment – Perform a technetium‑99m MAA scan and calculate LSF. If LSF > 20 % (glass) or > 15 % (resin), reduce the planned Y‑90 activity or choose an alternative therapy.
2. Dosimetry‑guided dosing – Use personalized dosimetry software to keep the cumulative lung dose < 30 Gy, the threshold linked with a higher pneumonitis risk.
3. Microsphere selection – Glass beads have a lower lung deposition rate than resin beads for equivalent tumor dose; selecting the appropriate type can minimize risk.
4. Staged treatments – For large tumor burden, consider fractionated Y‑90 infusions with interim lung‑dose checks.
5. Optimize pulmonary health – Encourage smoking cessation, treat COPD aggressively, and vaccinate against influenza and pneumococcus before embolization.
6. Coordinate systemic therapies – Schedule chemotherapy or immunotherapy at least 2 weeks apart from Y‑90 to decrease additive lung toxicity.

Complications

If not identified and treated promptly, radiation‑induced pneumonitis can evolve into serious sequelae:

• Acute respiratory failure – Severe hypoxemia requiring high‑flow oxygen or mechanical ventilation.
• Radiation‑induced pulmonary fibrosis – Permanent scarring leading to chronic dyspnea, reduced diffusion capacity, and decreased quality of life.
• Secondary bacterial or fungal infection – Steroid therapy can predispose to opportunistic pathogens.
• Exacerbation of pre‑existing lung disease – COPD or asthma may worsen, increasing hospitalizations.
• Impact on cancer treatment – Development of pneumonitis may delay or preclude further Y‑90 sessions, potentially affecting oncologic outcomes.

When to Seek Emergency Care

References

1. Yttrium‑90 radioembolization: Clinical outcomes and toxicity. *European Journal of Radiology*. 2017.
2. Pneumonitis – Symptoms and Causes. Mayo Clinic, 2023.
3. Pneumonia and Pneumonitis Clinical Information. CDC, 2022.
4. Pulmonary Fibrosis. Cleveland Clinic, 2024.
5. Radiation‑Induced Lung Injury. National Heart, Lung, and Blood Institute, 2021.
6. Pneumonia Fact Sheet. WHO, 2023.

```